Feb 14 |
Evoke Pharma Announces Closing of $7.5 Million Public Offering
|
Nov 30 |
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray
|
Nov 14 |
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
|
Nov 10 |
Evoke Pharma files to sell common stock and warrants
|
Nov 9 |
Evoke Pharma GAAP EPS of -$0.51, revenue of $1.56M
|
Nov 9 |
Evoke Pharma Reports Third Quarter 2023 Financial Results
|
Oct 31 |
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023
|